Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Px-102. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 known ✓ | Q96RI1 | 20/20 | 0.78 |
| ▸ | FXR2 | P51116 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Px-102 SCHEMBL17079090 | 0.96 | NR1H4 (0.85) | NR1H4FXR2 | |
| Px-102 SCHEMBL18347363 | 0.96 | NR1H4 (0.85) | NR1H4FXR2 | |
| Px-102 SCHEMBL18337964 | 0.96 | NR1H4 (0.85) | NR1H4FXR2 | |
| Px-102 SCHEMBL18337988 | 0.96 | NR1H4 (0.85) | NR1H4FXR2 | |
| Px-102 SCHEMBL18337986 | 0.96 | NR1H4 (0.85) | NR1H4FXR2 | |
| Px-102 SCHEMBL12098287 | 0.93 | NR1H4 (0.91) | NR1H4FXR2 | |
| Px-102 SCHEMBL28819610 | 0.93 | NR1H4 (0.91) | NR1H4FXR2 | |
| SCHEMBL18337987 | 0.89 | NR1H4 (0.85) | NR1H4FXR2 | |
| SCHEMBL17079095 | 0.89 | NR1H4 (0.85) | NR1H4FXR2 | |
| SCHEMBL18337990 | 0.89 | NR1H4 (0.85) | NR1H4FXR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3267991-A1 | TREATING LATENT AUTOIMMUNE DIABETES OF ADULTS WITH FARNESOID X RECEPTOR AGONISTS TO ACTIVATE INTESTINAL RECEPTORS | Salk Institute for Biological Studies (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2017078928-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-05-11 | — | — | WO | disclosed |
| EP-3116878-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | Salk Institute for Biological Studies (US) | 2017-01-18 | — | — | EP | disclosed |
| WO-2016149111-A1 | TREATING LATENT AUTOIMMUNE DIABETES OF ADULTS WITH FARNESOID X RECEPTOR AGONISTS TO ACTIVATE INTESTINAL RECEPTORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-09-22 | — | — | WO | disclosed |
| WO-2015138986-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2015-09-17 | — | — | WO | disclosed |